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1. Introduction 
The translocation of citrate or isocitrate from mito- 
chondria to the cytosol is an obligatory step for fatty 
acid synthesis from carbohydrates [l-5] . Low 
concentrations (20- 100 PM) of palmityl-CoA have 
been shown to inhibit citrate translocation across 
membranes of isolated mitochondria [6]. It has there- 
fore been suggested that long-chain fatty-acyl CoA 
derivatives are physiological regulators of fatty acid 
synthesis in liver. No drug with similar properties 
at such concentrations has been reported. The classical 
inhibitor of citrate transport, benzene-l ,2,3-tricarb- 
oxylate, is active in mitochondrial suspensions at 
5-l 0 mM only [ 51. Moreover, I have observed 
(unpublished data) that, when administered to rats, 
benzene-l ,2,3&icarboxylate has no or only slight 
action on liver fatty acid synthesis, presumably 
because sufficiently high cellular concentrations 
cannot be achieved in vivo. 
In this communication, it is shown that S- 
(tetradecyloxy)-2-furoic acid (compound I), a 
hypolipidemic agent which reduces fatty acid bio- 
synthesis in vivo [7], inhibits at low concentrations 
tricarboxylate anion translocation in membranes of 
isolated mitochondria. When administered orally 
to animals, liver fatty acid synthesis from [14C] 
alanine is inhibited. A direct relationship between 
the effects of I and two related compounds on 
citrate translocation and on liver fatty acid synthesis 
is reported. 
2. Materials and methods 
The structure of I is as follows: 





Two related compounds used in this work were: 
4-(tetradecyloxy) benzoic acid (II) and 3-[4-(tetra- 
decyloxy) benzoyl] acetic acid, benzyl ester (III). 
These three compounds were obtained from Merrell- 
National Laboratories, Cincinnati, Ohio. The Merrell 
designation is RMI 14,514 for I, RMI 13,640 for II 
and RMI 14,425 for III. These three compounds are 
members of a new class of drugs which produce hypo- 
lipidemic effects in rats ([7] and Belgian patents 
813 040 for I, 805 172 for II and 805 170 for III). 
A fourth hypolipidemic drug, Clofibrate (ethyl p- 
chlorophenoxyisobutyrate), was a gift from Dr J. 
Walker, ICI, Macclesfield, Cheshire, England. 
Liver mitochondria were prepared by conventional 
methods [8] from Sprague-Dawley male rats, 
200-250 g, (Charles River, France) fed ad libitum 
on a commercial diet (UAR, France) or from rats 
fed a fat-free diet [9] as described for in vivo studies. 
Mitochondrial protein content was determined by the 
method of Lowry et al. [lo] . The isocitrate influx 
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into isolated mitochondria was monitored by the 
rate of intramitochondrial NADH formation in 
response to the oxidation of externally added 
fhreo-Ds-isocitrate by mitochondrial NAD-isocitrate 
dehydrogenase, the conditions being as described 
by Chappell [ 111. Isocitrate was used instead of 
citrate to bypass the aconitase step, whose activity 
could be modified by the drugs under study. More- 
over, citrate and isocitrate cross mitochondrial 
membrane by similar mechanisms [3], Efflux of 
[14C]citrate from preloaded mitochondria was 
followed as described by Robinson et al. [ 121 and 
Halperin et al. [6]. 
For the studies of in vivo synthesis of fatty acids, 
rats (120- 130 g) were treated, to increase the synthesis 
of fatty acids in liver, by a 48 h fast followed by the 
feeding of a fat-free diet (UAR, France) for 3 h a 
day during 7 to 11 days. After this period, one or 
another of the above drugs was added to the same 
diet (10 g per day) in order to provide a dose of 
200 mg/kg/day. Non-anaesthetized rats were injected 
in the femoral vein, 2 hours after the last daily meal, 
with a solution of 0.9% (w/v) NaCl containing cry- 
ketoglutarate and radioactive alanine. Thirty minutes 
after injection rats were sacrificed and incorporation 
of label into newly synthesized fatty acids was 
determined. The procedure has been described by 
Sullivan et al. [9] . 
3. Results 
The kinetics of inhibition by I of isocitrate 
influx into mitochondria of rats fed a standard diet 
is shown in fig. 1. A competitive inhibition was 
observed. The apparent Ki was 1.4 I.IM while the 
apparent K, for three-Ds-isocitrate was 23 PM. For 
rats on a fat-free diet the values were 2.1 PM and 
26 PM respectively. Inhibition was identical whether 
I was added before or after the anti-porter anion, 
malate. Inhibition of isocitrate influx by 4 PM I was 
not altered when various malate concentrations, 
from 2.5 PM to 1 mM, were used. No inhibition of 
NAD-isocitrate dehydrogenase from disrupted mito- 
chondria was found with 20 PM I while, under the same 
conditions in intact mitochondria, isocitrate 
oxidation was inhibited 85%. Compound I inhibited 
[14C] citrate efflux from preloaded mitochondria 
as shown in fig.2 for rats fed a standard diet. The 
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Fig.1. Kinetics of inhibition by compound I of isocitrate 
influx into liver mitochondria from rats fed a standard diet 
ad libitum. Rat liver mitochondria (2 mg protein) were 
suspended in 2.0 ml of a medium containing 125 mM 
KCl, 20 mM Tris-HCl and 2 mM phosphate, pH 7.4 at 30°C. 
1 @M carbonyl cyanide, m-chlorophenyl-hydrazone was 
added, and after 3 min 0.2 pg/ml antimycin, followed by I 
and 0.25 mM malate. The rate of intramitochondrial NAD 
reduction, upon the addition of three-Ds-isocitrate at 
various concentrations, was monitored fluorometrically 
(excitation 340 nm, emission 460 nm). The reciprocal 
of the velocity of intra-mitochondrial NAD reduction is 
plotted against concentration of the inhibitor under three 
sets of conditions, as indicated in the figure. [S] : rhreo- 
Ds-isocitrate. The Ki is 1.4 PM. 
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Fig.2. Effects of compound I and clofibrate on the efflux 
of citrate from mitochondria isolated from rats fed a standard 
diet ad libitum and preloaded with [“Clcitrate. Efflux was 
initiated by the addition of non-labelled citrate (1 mM). 
Mitochondrial protein, 8 mg/ml; t = 18°C. 
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Table 1 
Effects of hypolipidemic agents (compounds I, II, III 
and clofibrate) on net in vivo incorporation of label 
from [U-Y] alanine into liver fatty acidsC 
Treatment group Liver weight In vivo lipogenesis 
dpm in fatty acids 
(N” of animals) (9) 
1. Control (5) 6.2 t 0.2 
Compound I (4) 6.4 f 0.2 
Clofibrate (5) 6.6 f 0.4 
2. Control (5) 7.2 + 0.4 
Compound II (5) 7.2 -f: 0.3 
3. Control (4) 6.6 + 0.4 
Compound III (4) 7.6 +_ 0.7 
Results are mean + SEM. 
a’p < 0.1, 
(mg liver/30 min) 
17.8 -t 2.3 
9.6 t 2.3b 
15.4 c 1.7 
15.8 f 1.2 
11.7 * 1.1” 
22.2 f 2.0 
17.1 f 2.6 
b p < 0.05, Student’s 2-tailed t-test. 
c In all cases drugs were added to the diet for 4 days at a 
dose of 200 mg/kg/day. Diet was fat-free and given 3 h a day. 
[U-“Clalanine, 80 mg (15 pCi)/kg of body weight, was 
injected to rats as described in the text. 
inhibition was also observed in mitochondria from 
rats on the fat-free regimen. The hypolipidemic agent 
clofibrate, which is known to inhibit purified acetyl- 
CoA carboxylase [ 131, had no inhibitory activity on 
citrate efflux. 
The effects of I, II, III and clofibrate on the in 
vivo rate of liver lipogenesis from [14C]alanine are 
reported in table 1. Compound I was the strongest 
inhibitor of label incorporation into fatty acids 
(46%) followed by II (26%) and III (23%). Under the 
same conditions clofibrate slightly inhibited liver 
fatty acid synthesis (13%). Using mitochondria 
isolated from rats on a standard diet, compounds I, 
II and III, each at a concentration of 25 PM, 
inhibited influx of three-Ds-isocitrate (25 PM) 
by 83%, 36% and 27%, respectively. At the same 
concentration clofibrate inhibited isocitrate influx 
by 5%. 
4. Discussion 
It is apparent from these results that: 
(1) Compound I, like palmityl-CoA, inhibited 
translocation of tricarboxylate anion across mito- 
chondrial membrane at low concentrations. This 
compound being highly lipophilic, such concentrations 
may be obtained in liver cells after treatment of 
animals with the drug at doses (100-200 mg/kg) 
which lower plasma triglycerides and cholesterol. 
(2) Compound I inhibited isocitrate influx into 
isolated mitochondria at lower concentrations than 
citrate efflux. However, the protein contents for 
the two assays were different. If active drug is bound 
to the citrate carrier, a more appropriate comparison 
is made by expressing concentrations in nmoles/mg’ 
of protein [6]. In this case, inhibition was observed 
at 5-20 nmol/mg of protein for both conditions. 
(3) Compound I had a greater affinity than the 
substrate for the tricarboxylate anion carrier. Indeed, 
the apparent Ki for I was approx. 10 times smaller 
than the KM for three-Ds-isocitrate. 
(4) In vivo liver fatty acid synthesis from [‘*Cl 
alanine was significantly inhibited by I. In alanine 
metabolism, the pyruvate formed is transported into 
mitochondria by a specific carrier. Pyruvate dehydro- 
genase is localized on the inner side of the inner 
membrane, and therefore fatty acid synthesis from 
alanine involves citrate formation in mitochondria 
and its efflux to the cytosol. These in vivo effects of 
I and those described on isolated mitochondria 
suggest hat pharmacological action of I is mediated 
through an inhibition of mitochondrial citrate transport. 
However, it is not excluded that I inhibits also 
acetyl-CoA carboxylase [ 141. 
(5) There was a direct relationship between the 
in vivo inhibition of fatty acid synthesis and the 
inhibition of isocitrate influx by I and two related 
compounds (II and III). This relationship further 
substantiates the hypothesis for the mechanism of 
action of I. 
(6) Clofibrate had only slight action on tricarb- 
oxylate anion transport and on liver fatty acid synthesis 
from [14C] alanine indicating that this drug and I 
have different effects on liver lipogenesis. 
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